NVS - Frequency Therapeutics Files For IPO For Hearing Loss Drug
Quick Take
Frequency Therapeutics (FREQ) has filed to raise gross proceeds of up to $100 million from a U.S. IPO, according to an S-1 registration statement.
The firm is developing therapeutics focused on repairing or reversing damage caused by a range of degenerative diseases.
FREQ has a potentially major collaboration for its lead program. I’ll provide an update when we learn more IPO details from management.
Company & Technology
Woburn, Massachusetts-based Frequency Therapeutics was founded in 2014 to develop drugs for patients suffering damage caused by degenerative diseases in the muscle, gastrointestinal